Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 3 of 33 · 1559 articles
Nutritional disorders in IBD (underweight/malnutrition, overweight/obesity, and muscle loss/sarcopenia) are common and affect treatment tolerance, recovery, and quality of life. Knowing how frequent these problems are...
The study identifies a specific fibroblast–macrophage interaction driven by collagen IV that may explain how chronic IBD inflammation progresses to fibrosis and cancer, highlighting possible new molecular targets to...
Children with IBD can present differently than adults and may show early signs outside the gut. The special-issue papers highlight improved, less-invasive diagnostic tools and increasing use of targeted biologic...
Fibrostenotic strictures are a major unmet need in Crohn’s disease because anti-inflammatory drugs often cannot reverse established scarring; IL-11 is a biologically plausible target that might selectively affect...
Surgical site infection is a common and serious complication after IBD surgery. The paper highlights that antibiotic-resistant bacteria (ESBLs, MRSA) were common in this Saudi cohort and that standard cephalosporin...
Some infections (here, HIV) can closely mimic very early onset IBD. Recognizing progressive lymphopenia or unusual infections can change diagnosis and treatment, which matters because immunosuppression can worsen...
IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
Researchers and clinicians want biomarkers that predict outcome or tailor treatment. This study suggests a mucosal gene-expression score is prognostic and declines in responders, but it does not yet show the score...
MRE is a widely used, noninvasive test that increasingly helps characterize disease phenotype and prognosis in Crohn's disease and IBD, which can affect monitoring and treatment planning.
MRE is a key, non-radiating test for Crohn’s disease that can show active inflammation and complications that endoscopy may miss, so updates on technique matter for diagnosis and monitoring. Better imaging technique can...
Patients and clinicians use the term "disease burden" to describe more than inflammation alone; it affects symptoms, daily function, mental health, and healthcare use. A clearer, integrated way to measure burden could...
Vitamin D deficiency was very common in this IBD cohort and was linked to Crohn’s disease and female sex, which may matter because deficiency can affect bone health and immune regulation in people with IBD.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Pediatrics and family. The original article is from Nutrients.
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Translational...
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...
Noninvasive GI ultrasound (including Doppler/CEUS) could reduce the need for frequent endoscopies for monitoring IBD activity and, when combined with biomarkers, may improve accuracy of disease assessment. However,...
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future...
A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.
A registry focused on "difficult-to-treat" IBD aims to describe how often and why patients become treatment-refractory, how their disease and treatments evolve over time, and which outcomes (hospitalization, surgery,...
Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...
This early-phase trial explores a novel, targeted bacteriophage treatment for pouchitis linked to an Aeromonas-associated pathogen (MTB). For people with pouchitis after IPAA, a safe, effective phage therapy could...
Predicting early need for infliximab could help identify children with Crohn’s disease who may benefit from earlier biologic therapy instead of prolonged conventional treatment. A reliable prediction tool may shorten...
Patients with IBD have an increased colorectal cancer risk, and those with PSC, extensive colitis, severe inflammation, or prior dysplasia are at especially high risk. High-quality surveillance techniques can improve...
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Ct Enterography. The original article is from idp.springer.com.
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
This study explores a non-drug dietary supplement approach aimed at changing host–microbiome interactions after surgery — a potentially relevant prevention strategy for postoperative Crohn's disease recurrence if later...
A phase 2 trial testing an oral integrin α4β7 inhibitor could matter because it explores a potential new mechanism for treating moderately to severely active ulcerative colitis, including patients who have failed other...
This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...
Microbiota-derived metabolites are linked to inflammation and gut barrier function, so they could become biomarkers or therapeutic targets for Crohn’s disease and ulcerative colitis. Patients may see future tests or...
Findings suggest GM-CSF signaling may help limit epithelial injury and shape immune cell states in Crohn’s disease, which could be relevant to understanding inflammation and future therapies targeting innate immunity or...
The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...
Protein biomarkers that predict IBD years before diagnosis could enable earlier detection, inform risk-stratified monitoring, and reveal early disease pathways that might be targeted to prevent or delay onset.
Muscle loss (myopenia) can persist in Crohn's disease even after weight recovery and clinical remission, which may affect long-term outcomes. Identifying persistent muscle depletion with body composition measures could...
If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...
Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...
The study found higher recorded rates of hidradenitis suppurativa in people with Crohn’s disease and psoriatic arthritis, and a smaller increase in ulcerative colitis, suggesting clinicians should consider asking about...
Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...
Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...
This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...
This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.
